Clinical Trial Update: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa [Phase 3]

View source ↗

Summary

Phase 3 study update for FCX-007 in Recessive Dystrophic Epidermolysis Bullosa. Results were posted in April 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• FCX-007

Snippet

Sponsor: Castle Creek Biosciences, LLC. | Conditions: Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-04-01